Aesica adds dev-stage formulation capabilities for potent APIs and controlled drugs

By Staff reporter

- Last updated on GMT

Aesica adds dev-stage formulation capabilities for potent APIs and controlled drugs

Related tags Pharmacology

Aesica has doubled early formulation development capacity and added controlled drug handling capabilities at its manufacturing facility in Queenborough, UK.

The expansion - financial terms of which were not disclosed - means the UK contract manufacturing organisation (CMO) can develop and manufacture a customer product from early formulation development through clinical manufacture and into commercialization.

The expansion also means Aesica can now conduct formulation development work on highly potent active pharmaceutical ingredients (APIs) and controlled drugs. Previously the firm could only offer such services for commercial-stage projects.

Managing director Ian Muir cited customer demand as the driver for the expansion.

 “We have taken the strategic initiative to ensure that our high capacity Queenborough Development Centre, which doubles our development capacity, combined with our commercial manufacturing capabilities at the facility, provides a complete service offering for formulation, development and product manufacturing for multiple customers​.” 

He added that: ‘High potency is a key contract services market, with strong growth potential, requiring a mix of highly specialised and advanced technological skills and capabilities​.”

The investment follows a few months after Consort Medical-owned Aesica relocated its clinical trial supply manufacturing operations to the Queenborough.

Previously, operations were based at a leased facility at the BioCity biotech and drug production hub in Nottingham.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars